Hill-Rom Holdings, Inc. (NYSE:HRC) Shares Acquired by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC increased its holdings in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 10.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,080 shares of the medical technology company’s stock after buying an additional 14,223 shares during the period. Parametric Portfolio Associates LLC owned about 0.22% of Hill-Rom worth $15,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Vanguard Group Inc boosted its position in Hill-Rom by 0.6% in the 3rd quarter. Vanguard Group Inc now owns 5,916,827 shares of the medical technology company’s stock worth $558,549,000 after purchasing an additional 34,369 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Hill-Rom by 4.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,400 shares of the medical technology company’s stock worth $390,000 after acquiring an additional 189 shares during the last quarter. Xact Kapitalforvaltning AB increased its position in shares of Hill-Rom by 5.4% during the 4th quarter. Xact Kapitalforvaltning AB now owns 9,802 shares of the medical technology company’s stock worth $868,000 after purchasing an additional 500 shares during the last quarter. Advisors Asset Management Inc. increased its position in shares of Hill-Rom by 41.4% during the 4th quarter. Advisors Asset Management Inc. now owns 18,499 shares of the medical technology company’s stock worth $1,638,000 after purchasing an additional 5,417 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Hill-Rom by 40.1% during the 4th quarter. Rhumbline Advisers now owns 183,809 shares of the medical technology company’s stock worth $16,276,000 after purchasing an additional 52,630 shares during the last quarter. Hedge funds and other institutional investors own 81.29% of the company’s stock.

Hill-Rom stock traded up $0.37 during midday trading on Monday, reaching $104.99. 283,200 shares of the stock traded hands, compared to its average volume of 487,072. The business has a 50-day simple moving average of $100.98. Hill-Rom Holdings, Inc. has a 12-month low of $81.82 and a 12-month high of $108.68. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of 22.10, a PEG ratio of 1.81 and a beta of 0.92. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.27 and a current ratio of 1.69.

Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, April 26th. The medical technology company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.03. The company had revenue of $714.20 million during the quarter, compared to analysts’ expectations of $705.59 million. Hill-Rom had a return on equity of 21.30% and a net margin of 7.93%. Hill-Rom’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the business posted $1.05 EPS. On average, analysts expect that Hill-Rom Holdings, Inc. will post 5.05 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 21st were paid a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 0.80%. The ex-dividend date was Thursday, June 20th. Hill-Rom’s payout ratio is presently 17.68%.

A number of analysts recently issued reports on the company. Zacks Investment Research raised Hill-Rom from a “hold” rating to a “buy” rating and set a $118.00 price objective for the company in a research report on Tuesday, April 16th. ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a research report on Tuesday, June 11th. Barclays raised their target price on Hill-Rom from $103.00 to $108.00 and gave the company an “equal weight” rating in a report on Monday, April 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $116.00 target price on shares of Hill-Rom in a report on Monday, March 11th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Hill-Rom presently has an average rating of “Buy” and an average target price of $108.00.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Further Reading: What is the Gross Domestic Product (GDP)?

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.